Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small-cell lung cancer (NSCLC). Exon 19 deletion and L858R point mutation are the most commonly encountered EGFR mutations in NSCLC, and they predic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Xue, Zhang Xiao, Wen, Wang Xiu, Zhuang, Yu, Hua, Zang Jian, Xia, Yang Ni
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2016
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998065/
https://ncbi.nlm.nih.gov/pubmed/27588191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.956
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados